GT Biopharma Inc. (NASDAQ:GTBP) on Thursday said it submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) in December 2025 for GTB-5550 TriKE for solid tumors. GTB-5550 TriKE is a B7-H3-targeted natural killer (NK) cell engager for B7-H3-expressing…
Continue reading...